Records containing: Squamous Cell Carcinoma of the Head and Neck
This is the wording recorded or indexed by the source. An agency index term is not necessarily an authorised indication. Co-listed drug names are not linked to this term as a treatment relationship.
Follow recorded terms in Drug Alerts for Android. Free includes unlimited local condition follows and an on-open recent-record watchlist. Plus adds no ads and personal organization tools.
All
FDA submission records
EMA medicine records
ClinicalTrials.gov record updates
ClinicalTrials.gov records with results posted
-
CLINICAL_TRIALS study record update · 2026-09-14ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
-
CLINICAL_TRIALS study record update · 2026-04-24Intratumoral Ipilimumab in Head and Neck Cancer
-
CLINICAL_TRIALS study record update · 2026-04-24Safety and Efficacy of Pertuzumab Combined With Lenvatinib for Neoadjuvant Treatment of Locally Advanced Squamous Cell Carcinoma of the Head and Neck: A Single-Arm, Single-Center Clinical Study.
-
CLINICAL_TRIALS study record update · 2026-04-20A Phase 1 Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
-
CLINICAL_TRIALS study record update · 2026-04-07A Phase 1 Study of PF-08046052/SGN-EGFRd2 in Advanced Solid Tumors
- Organize your saved records without ads with Plus.
-
CLINICAL_TRIALS study record update · 2026-04-02ClinicalTrials.gov study NCT02510859
-
CLINICAL_TRIALS study record update · 2026-03-27Neoadjuvant Ficerafusp Alfa With Pembrolizumab in Resectable Squamous Cell Carcinoma of the Head and Neck: a Phase 2 Trial
-
CLINICAL_TRIALS study record update · 2026-03-27Phase II Trial of Neoadjuvant Chemotherapy (NAC) Alone or in Combination With Immunotherapy Vaccine PRGN-2009 in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal (Head and Neck) Cancer
-
CLINICAL_TRIALS study record update · 2026-03-25Phase I Study of Afatinib With Postoperative Radiation Therapy for Intermediate and High Risk Squamous Cancer of the Head and Neck (SCCHN)
-
CLINICAL_TRIALS study record update · 2026-03-16A Phase 2 Study of Brentuximab Vedotin in Combination With Pembrolizumab in Participants With Metastatic Solid Malignancies
-
CLINICAL_TRIALS study record update · 2026-03-02Randomized Phase II Study of DCE-MRI-based Dose Escalation for Poor-prognosis and Neck Cancer
-
CLINICAL_TRIALS study record update · 2026-02-27A Phase 1 Trial of CTLA-4 Inhibition, With or Without Cetuximab, and in Combination With Memory-like Natural Killer (NK) Cell Immune Cell Therapy in Advanced Head & Neck Cancer
-
CLINICAL_TRIALS study record update · 2026-02-23FIRST-IN-HUMAN (FIH), OPEN-LABEL, PHASE 1 DOSE ESCALATION AND EXPANSION STUDY DESIGNED TO EVALUATE THE SAFETY, TOLERABILITY, PK, PD, AND PRELIMINARY CLINICAL ACTIVITY OF PF-07826390 AS A SINGLE AGENT OR IN COMBINATION TREATMENT FOR PARTICIPANTS WITH ADVANCED SOLID TUMORS.
-
CLINICAL_TRIALS study record update · 2026-01-28An Open-Label, Phase 2 Efficacy Study With Window of Opportunity Immune Assessment of Pembrolizumab in Relapsed, Locally Recurrent Squamous Cell Carcinoma of the Head and Neck (SCCHN)
-
CLINICAL_TRIALS study record update · 2026-01-20Study of Intratumoral Injections of VLPONC-01 in Head and Neck Cancer
-
CLINICAL_TRIALS study record update · 2026-01-08Multi-Omic Assessment of Squamous Cell Cancers Receiving Systemic Therapy
-
CLINICAL_TRIALS study record update · 2026-01-08A Phase II Trial of Personalized Immunotherapy in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck That Have Progressed on Prior Immunotherapy
-
CLINICAL_TRIALS study record update · 2026-01-06Decisional Conflicts, Health-related Quality of Life and Satisfaction With Care in High-risk Cutaneous Squamous Cell Carcinoma in the Head-neck Region: Validated Questionnaires
-
CLINICAL_TRIALS study record update · 2026-01-06A Randomized Controlled Clinical Study of De-Escalation Surgery Following Immunotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma
-
CLINICAL_TRIALS study record update · 2025-12-18Phase I Dose-escalation Study of PEmbrolizumab (MK3475) Anti-PD1 Immune Checkpoint Inhibitor Combined With Radical Chemoradiotherapy in Patients With Stage IV Squamous Cell Carcinoma of the Head and Neck
-
CLINICAL_TRIALS study record update · 2025-12-05A Phase 1b Trial of the IRX-2 Regimen and Durvalumab (MEDI4736), in Patients With Incurable Head and Neck Squamous Cell Carcinoma
-
CLINICAL_TRIALS study record update · 2025-10-14An Open-Label, Multicenter, Phase 1/1b Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies
-
CLINICAL_TRIALS study record update · 2025-10-08A Randomized, Double-Blind Placebo-Controlled, Phase 3 Study of Debio 1143 in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitive Chemoradiotherapy (TrilynX)
-
CLINICAL_TRIALS study record update · 2025-10-01A Randomized, Double-blind Phase II Study of Adjuvant Pembrolizumab Versus Placebo in Head and Neck Cancers at High Risk for Recurrence - the PATHWay Study.
-
CLINICAL_TRIALS study record update · 2025-09-17A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY, TOLERABILITY, PHARMACOKINETIC, PHARMACODYNAMIC, AND ANTITUMOR ACTIVITY OF PF-07820435 AS MONOTHERAPY AND IN COMBINATION IN PARTICIPANTS WITH ADVANCED SOLID TUMORS